|View printer-friendly version|
|September 30, 2013 9:08 a.m.|
|Teva In-Focus: A New Webinar Series for the Investment Community Focusing on Teva’s R&D Activities|
- Upcoming Webinar:
This new webinar series provides an in-depth view of Teva’s R&D strategies and progress in primary therapeutic areas in a format that is focused, detailed, and accessible.
Teva In-Focus kicks off on
Teva In-Focus will include a review of the global market and unmet needs, our approach to innovation and therapeutic development, and a deep dive into key projects that we believe will drive Teva’s future growth in the respiratory market.
A question and answer session will follow the presentation.
Teva's Safe Harbor Statement under the
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products, competition for our innovative products, especially COPAXONE® (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our specialty, including innovative, R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S. and